Abstract
Simple SummaryAcute myeloid leukemia (AML) is a type of blood malignancy particularly affecting the myeloid lineage and one of the most common types of leukemia in adults. It is characterized by high heterogeneity among patients leading to immune escape and disease relapse, which challenges the development of immunotherapies such as chimeric antigen receptor (CAR) T-cells. In this way, the aim of our work was to establish the modular RevCAR platform as a combinatorial tumor targeting approach for the treatment of AML. Herein, we demonstrate the preclinical flexibility and efficiency of RevCAR T-cells in targeting patient-derived AML cells expressing CD33 and CD123. Furthermore, AND gate logic targeting these antigens was successfully established using the RevCAR platform. These accomplishments pave the way towards the future clinical translation of such an improved and personalized immunotherapy for AML patients aiming long-lasting anticarcinogenic responses.Clinical translation of novel immunotherapeutic strategies such as chimeric antigen receptor (CAR) T-cells in acute myeloid leukemia (AML) is still at an early stage. Major challenges include immune escape and disease relapse demanding for further improvements in CAR design. To overcome such hurdles, we have invented the switchable, flexible and programmable adaptor Reverse (Rev) CAR platform. This consists of T-cells engineered with RevCARs that are primarily inactive as they express an extracellular short peptide epitope incapable of recognizing surface antigens. RevCAR T-cells can be redirected to tumor antigens and controlled by bispecific antibodies cross-linking RevCAR T- and tumor cells resulting in tumor lysis. Remarkably, the RevCAR platform enables combinatorial tumor targeting following Boolean logic gates. We herein show for the first time the applicability of the RevCAR platform to target myeloid malignancies like AML. Applying in vitro and in vivo models, we have proven that AML cell lines as well as patient-derived AML blasts were efficiently killed by redirected RevCAR T-cells targeting CD33 and CD123 in a flexible manner. Furthermore, by targeting both antigens, a Boolean AND gate logic targeting could be achieved using the RevCAR platform. These accomplishments pave the way towards an improved and personalized immunotherapy for AML patients.
Highlights
Treatment of acute myeloid leukemia (AML) is still challenged by inadequate longlasting anticarcinogenic responses due to its heterogeneity and poorly known resistance mechanisms [1]
Reverse CAR (RevCAR) T-cells are engineered to express RevCARs that consist of the peptide epitopes E5B9 or E7B6 instead of a single-chain fragment variable that is commonly used as extracellular domain in conventional second-generation chimeric antigen receptor (CAR)
The purpose of this study was to show the flexibility of the RevCAR platform to be adapted to target myeloid malignancies like AML
Summary
Treatment of acute myeloid leukemia (AML) is still challenged by inadequate longlasting anticarcinogenic responses due to its heterogeneity and poorly known resistance mechanisms [1]. The enthusiasm to exploit CAR T-cell-based technologies targeting these antigens is reflected by the promising number of early clinical trials currently ongoing In this regard, an impressive and promising phase I clinical trial using UniCAR T-cells targeting CD123 for the treatment of CD123-positive hematologic and lymphoid malignancies (NCT04230265) proved to be a breakthrough. Given the heterogeneity of antigen expression on AML cells, combinatorial targeting approaches are required as an improved therapeutic tool Bearing this in mind, and based on our experience working with conventional CAR T-cells [13] and modular Ab-based systems to redirect T-cells [14], we developed the adaptor Reverse CAR (RevCAR) platform [15]. The small size of the RevCAR epitope molecules, with the E5B9 epitope
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
